Exopharm Limited has signed a Master Collaborative Services Agreement (MSA) with the Astellas Institute for Regenerative Medicine (AIRM). Under the terms of the MSA, AIRM will pay Exopharm fees of up to USD 481,000 for both projects over a period of around 15 months, starting in March 2022. The MSA enables laboratory work to demonstrate the effectiveness of Exopharm's LEAP, LOAD and EVPS technologies utilising AIRM's cell-based therapeutic technologies. The LEAP project will commence in early 2022 at Exopharm's laboratories in Melbourne and will seek to validate the use of Exopharm's LEAP technology platform to purify exosomes derived from two proprietary AIRM cell lines. A second phase of this project will involve
transferring the LEAP technology to AIRM research headquarters located in Massachusetts USA for their further evaluation and use.